Group 1 - Goldman Sachs initiates coverage on Connora with a "Buy" rating and a target price of HKD 92.67 [1] - The company's first commercial product, Stapokibart, has been approved in mainland China for atopic dermatitis, chronic sinusitis, and seasonal allergic rhinitis [1] - Goldman Sachs believes Stapokibart's first-mover advantage in these areas will establish a valuation foundation, with peak sales expected to exceed HKD 5 billion by 2035 [1] Group 2 - The firm anticipates greater growth momentum from CM512, which is expected to be a superior option for asthma and chronic obstructive pulmonary disease [1] - Projected global sales for CM512 are expected to reach USD 3.3 billion before the point of sale (PoS) stage and USD 694 million after by 2035 [1]
大行评级丨高盛：首予康诺亚“买入”评级及目标价92.67港元